

Remarks

In the specification, page 14, line 39, compound number 35; page 19, compound number 35 and page 41, lines 30 and 31 have been amended to correct minor errors. In the claims, claim 6, compound number 35 has also been amended to correct minor errors. No new matter is incorporated herewith, as the amendments are made to correct obvious errors, as follows.

On page no. 19, it is clearly mentioned that the starting material for Compound No. 36 is Compound No. 29 (which contains a cyclopentyl ring and has the R configuration at the C-2 position). Therefore, the IUPAC name of Compound No. 36 is correct on pages 15 and 61. However, there is an obvious error on page 41, as explained here.

Upon review of page 41 (Example 35), Compound No. 29 is used as the starting material which leads to formation of Compound No. 36, not Compound No. 35. Therefore we have replaced Compound No. 35 with Compound No. 36 in Example 35 and Compound No. 36 with Compound No. 35 in Example 36.

Now, with respect to Compound No. 35, as apparent from the above, it is thus confirmed that correct IUPAC name of Compound No. 35 is

(2S)-(-)- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide.L(+)-tartrate salt

Therefore the IUPAC name of Compound No. 35 is incorrect on pages 14 and 61, and should be amended accordingly.

Also, as per Example 36, the starting material for Compound No. 35 is Compound No. 32, therefore on page 19, following correction has been made:

35	<i>L-(+) Tartaric acid salt of compound shown in Compound Number 28 32 in this table</i>
----	--


Applicants submit that one of ordinary skill recognizes both the existence of these errors in the specification, and the appropriate corrections, as set forth herein.

Entry of this Preliminary Amendment before examination is respectfully requested.

Authorization is hereby provided to charge any required fees to Deposit Account No. 50-0912.

Respectfully submitted,

MEHTA et al.

By: 
George E. Heibel
Reg. No. 42,648

Date: February 7, 2006

Correspondence Address:

Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540
Telephone: (609) 720-5334
Facsimile: (609) 514-9779